logo
Plans to list etomidate as illegal drug: Ong Ye Kung, Typhoon Wipha causes major flight disruptions: Singapore live news

Plans to list etomidate as illegal drug: Ong Ye Kung, Typhoon Wipha causes major flight disruptions: Singapore live news

Yahoo3 days ago
Singapore's Health and Home Affairs Ministries are working to list etomidate, which is being abused via e-vaporisers, under the Misuse of Drugs Act (MDA), Health Minister Ong Ye Kung said on Sunday (20 July). This paves the way for abusers and traffickers of Kpods – vapes containing etomidate – to be treated in the same way as those who abuse or traffic drugs like nimetazepam (Erimin-5), with mandatory rehabilitation and jail time for repeat offenders.
Currently, etomidate is listed under the Poisons Act. Under this law, abusers face only a fine. Sellers face possible jail time of up to two years. Ong said this will be done in the coming weeks. He added that it will be an interim measure until further changes can be made to the law to tackle the vaping scourge in Singapore. Read more about why there are plans to list etomidate under the MDA.
Typhoon Wipha toppled trees and caused major flight disruptions Sunday (20 July) in Hong Kong and at some nearby airports in China as it moved west off the southern coast of the country. Earlier on Sunday morning, the Hong Kong Observatory issued a hurricane signal No. 10, its highest warning. Find out more about Typhoon Wipha, which was later downgraded to a severe tropical storm.
Read more in our live blog below, including the latest local and international news and updates:
MOH, MHA working to list etomidate as illegal drug: Ong Ye Kung
Singapore's Health and Home Affairs Ministries are working to list etomidate, which is being abused via e-vaporisers, under the Misuse of Drugs Act (MDA), Health Minister Ong Ye Kung said on Sunday (20 July).
This paves the way for abusers and traffickers of Kpods – vapes containing etomidate – to be treated in the same way as those who abuse or traffic drugs like nimetazepam (Erimin-5), with mandatory rehabilitation and jail time for repeat offenders.
Currently, etomidate is listed under the Poisons Act. Under this law, abusers face only a fine. Sellers face possible jail time of up to two years.
Ong said this will be done in the coming weeks. He added that it will be an interim measure until further changes can be made to the law to tackle the vaping scourge in Singapore.
Read more about why there are plans to list etomidate under the MDA.
Typhoon Wipha causes damage, disrupt flights, before weakening to severe tropical storm
Typhoon Wipha toppled trees and caused major flight disruptions Sunday (20 July) in Hong Kong and at some nearby airports in China as it moved west off the southern coast of the country. Earlier on Sunday morning, the Hong Kong Observatory issued a hurricane signal No. 10, its highest warning.
Airports in Hong Kong, Shenzhen, Zhuhai and the casino hub of Macao canceled or postponed flights for most of the day, according to their websites. Hong Kong grounded at least 400 flights, affecting around 80,000 passengers, broadcaster RTHK said. Some high-speed train services were also suspended.
The typhoon stayed just offshore until about 6 pm, when it made landfall in a coastal area of Taishan city in Guangdong province, China's National Meteorological Center said. It then weakened to a severe tropical storm with maximum sustained winds of 108 kph.
Singapore's Health and Home Affairs Ministries are working to list etomidate, which is being abused via e-vaporisers, under the Misuse of Drugs Act (MDA), Health Minister Ong Ye Kung said on Sunday (20 July).
This paves the way for abusers and traffickers of Kpods – vapes containing etomidate – to be treated in the same way as those who abuse or traffic drugs like nimetazepam (Erimin-5), with mandatory rehabilitation and jail time for repeat offenders.
Currently, etomidate is listed under the Poisons Act. Under this law, abusers face only a fine. Sellers face possible jail time of up to two years.
Ong said this will be done in the coming weeks. He added that it will be an interim measure until further changes can be made to the law to tackle the vaping scourge in Singapore.
Read more about why there are plans to list etomidate under the MDA.
Typhoon Wipha causes damage, disrupt flights, before weakening to severe tropical storm
Typhoon Wipha toppled trees and caused major flight disruptions Sunday (20 July) in Hong Kong and at some nearby airports in China as it moved west off the southern coast of the country. Earlier on Sunday morning, the Hong Kong Observatory issued a hurricane signal No. 10, its highest warning.
Airports in Hong Kong, Shenzhen, Zhuhai and the casino hub of Macao canceled or postponed flights for most of the day, according to their websites. Hong Kong grounded at least 400 flights, affecting around 80,000 passengers, broadcaster RTHK said. Some high-speed train services were also suspended.
The typhoon stayed just offshore until about 6 pm, when it made landfall in a coastal area of Taishan city in Guangdong province, China's National Meteorological Center said. It then weakened to a severe tropical storm with maximum sustained winds of 108 kph.
Typhoon Wipha toppled trees and caused major flight disruptions Sunday (20 July) in Hong Kong and at some nearby airports in China as it moved west off the southern coast of the country. Earlier on Sunday morning, the Hong Kong Observatory issued a hurricane signal No. 10, its highest warning.
Airports in Hong Kong, Shenzhen, Zhuhai and the casino hub of Macao canceled or postponed flights for most of the day, according to their websites. Hong Kong grounded at least 400 flights, affecting around 80,000 passengers, broadcaster RTHK said. Some high-speed train services were also suspended.
The typhoon stayed just offshore until about 6 pm, when it made landfall in a coastal area of Taishan city in Guangdong province, China's National Meteorological Center said. It then weakened to a severe tropical storm with maximum sustained winds of 108 kph.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

China Reports Record Outbreak of Painful Mosquito-Borne Virus
China Reports Record Outbreak of Painful Mosquito-Borne Virus

Bloomberg

timean hour ago

  • Bloomberg

China Reports Record Outbreak of Painful Mosquito-Borne Virus

A city in China's southern industrial hub has recorded more than 3,100 chikungunya cases so far this month, the country's biggest outbreak of the mosquito-borne virus since it first emerged in the mainland nearly two decades ago. Foshan city — in Guangdong Province, just north of Hong Kong — first reported an imported chikungunya case earlier in July, China's national broadcaster CCTV said, citing briefings from local authorities.

Introducing Inner Harmony Spa Sg presenting Singapore's best facials, massages, energy healing treatments in CBD
Introducing Inner Harmony Spa Sg presenting Singapore's best facials, massages, energy healing treatments in CBD

Yahoo

timean hour ago

  • Yahoo

Introducing Inner Harmony Spa Sg presenting Singapore's best facials, massages, energy healing treatments in CBD

SINGAPORE, July 23, 2025 (GLOBE NEWSWIRE) -- Tucked away in the lively North Bridge district, Inner Harmony is a sanctuary of wellness—blending Asian traditions with European spa innovations to deliver transformative experiences. Whether one is seeking relaxation or rejuvenation, their comprehensive suite of services caters thoughtfully to every wellness need. Holistic Wellness & Spa for for Rejuvenation: Inner Harmony has designed to complement other therapies, their wellness services include: M3 Vibrational Training: A full-body workout without weights—effective, accessible, and gym-free. Therm O' Draine: Quietly harnessing heat to detoxify, reduce puffiness, and improve circulation. Manual Lymphatic Drainage: A precise technique from Dr. Vodder's lineage that effectively supports the lymphatic system. All services are tailored to the client's unique wellness journey, mapped by trained therapists to ensure lasting, visible results. Massage Therapies By Inner Harmony : They offers a spectrum of massage options tailored to soothe tension and restore vitality: Full Body Massage: A deeply relaxing treatment featuring bespoke aromatic essential oils that melt away stress and body aches. Hot Stone Massage: Warm stones strategically placed on acupressure points ease tight muscles and enhance circulation Herbal Fusion: Combining Swedish massage with a Thai herbal compress to detoxify, relieve inflammation, and boost lymphatic flow Spa Trex: An innovative dual method mixing human touch with neuro-stimulation, deeply balancing body and mind Facial Treatments - Inner Harmony : Their facial services utilize Alissi Bronte, a renowned natural cosmetic brand, to revitalize skin with premium, aromatic formulations .From gentle cleanses to intensive therapies, each session is customized to illuminate and rejuvenate. Slimming Solutions: Inner Harmony's slimming services employ cutting-edge methods like M3 Vibrational Training and Therm O' Draine, helping one sculpt and tone for wellness and confidence Meet the Visionary: Mr. Ananda Rajah At the heart of Inner Harmony is Mr. Ananda Rajah, an inspiring entrepreneur awarded the 2009 Spirit of Enterprise. He was honored for leading Atos Wellness and for contributing to societal well-being through corporate social responsibility Mr. Rajah also spearheaded the Spa, Beauty & Wellness Alliance (SBWA), fostering ethics and consumer confidence in Singapore's spa industry. His dedication has helped countless customers recover unutilized treatments from shuttered spas, reinforcing trust and transparency. Voices of Satisfaction Their Facebook and Instagram channels light up with heartfelt reviews. One recent comment reads. - 'Recharge your mind and body with our soothing and rejuvenating massage treatments. Experience the healing touch of our skilled therapists.' (Ref: Facebook Reviews) On Facebook, a guest noted:'Thank you Inner Harmony and The Founder Mr Anandha Raja for the warm welcome and thoughtful gift and Inspiring book.' (Ref: Facebook Reviews). These authentic testimonials reflect the spa's comforting atmosphere and the sincerity of its service. Why Choose Inner Harmony? > Holistic expertise: Diverse services that address both aesthetic goals and deep wellness needs. > Founder's integrity: A visionary leader who champions ethical business and community care. > Personalized journeys: Tailored treatments designed around ones goal and well-being. > Effortless booking: Online portal and responsive support make scheduling easy. > Proven customer love: Joyful testimonials speak volumes. Final Thoughts: Inner Harmony beckons as a place of visceral calm and refined care. Guided by founder Mr. Ananda Rajah's ethos and enriched by a suite of carefully curated services, this sanctuary caters to anyone seeking balance, beauty, and inner renewal. Whether one is recovering from a stressful week, looking to sculpt and tone, or simply longing for a peaceful spa day, Inner Harmony offers a retreat one will want to revisit again and again. Book the session at Level 3, North Bridge Road, or via their online portal—and step into a world where wellness meets harmony. Address & Operating Hours: Inner Harmony @ 25 North Bridge, Level 3, #03-02/03, North Bridge, Singapore 179104 Hours: Monday-Saturday, 11 am-10 pm Email: enquiries@ | Phone: +65- 67374449 / +65- 6841 9926 Booking & Contact Details: Booking is seamless via Inner Harmony's online portal, with managed one-treatment-per-day scheduling and customer service confirmations within 1 business day. For immediate appointments or modifications, call the centre at +65-6841 9926 Media Contact: Organization: Synergy Global Enterprise LLC Name: Gopi Divecha Contact Number: +6586940671 Address: 111 North Bridge Road #21–01, Singapore 179098 Website: Email: gopi@ Disclaimer: This content is provided by Inner Harmony. The statements, views, and opinions expressed in this column are solely those of the content provider. The information shared in this press release is not a solicitation for investment, nor is it intended as investment, financial, or trading advice. It is strongly recommended that you conduct thorough research and consult with a professional financial advisor before making any investment or trading decisions. Please conduct your own research and invest at your own in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer
Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

Yahoo

time3 hours ago

  • Yahoo

Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. ( ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in first-line treatment for advanced metastatic colorectal cancer (mCRC). This randomized, controlled, multi-center Phase III clinical trial for first-line treatment of mCRC is one of the company's key initiatives to address the significant unmet clinical need worldwide with ivonescimab. Colorectal cancer remains the third most common cancer globally and the second leading cause of cancer-related deaths. In 2022, over 1.9 million new cases were reported, with approximately 904,000 deaths. Of these, about 95% of mCRC cases are classified as microsatellite stable (MSS) or proficient mismatch repair (pMMR), which traditionally show poor responses to immunotherapy and the tumors are often referred to as an "immune desert." For first-line treatment of MSS/pMMR-type mCRC, which represents up to 95% of cases, several PD-1/L1 inhibitors have been explored in multiple international studies. However, the efficacy has been limited, and as of now, no first-line immunotherapy has been approved globally for patients with pMMR/MSS-type mCRC. Chemotherapy combined with targeted therapies (such as bevacizumab, cetuximab, etc.) remains the standard first-line treatment for mCRC, though its overall efficacy is limited, with a five-year survival rate for advanced patients of less than 20%. Bevacizumab is the most well-established and clinically impactful treatment in the mCRC space. It is also one of the core indications of bevacizumab. At the 2024 European Society for Medical Oncology (ESMO) Congress, Professor Yanhong Deng from the Sixth Affiliated Hospital of Sun Yat-sen University, presented promising Phase II efficacy data of ivonescimab in combination with chemotherapy for first-line treatment of MSS/pMMR-type mCRC. The combination of ivonescimab with FOLFOXIRI demonstrated compelling anti-tumor activity in this hard to treat patient population, with an overall response rate (ORR) of 81.8% and a disease control rate (DCR) of 100%. After a median follow-up of 9 months, the median progression-free survival (mPFS) was not reached, with a 9-month PFS rate of 81.4%. Regardless of KRAS/BRAF mutation status, patients can benefit from ivonescimab combination therapy. The results published at the 2024 ESMO suggest that ivonescimab may offer a significant improvement over existing treatment options for MSS/pMMR mCRC patients. The Phase III trial AK112-312/HARMONi-GI6 can potentially further validate the clinical benefits of ivonescimab in this setting, offering a novel first-line immunotherapy treatment option for patients with advanced mCRC. Forward-Looking Statement of Akeso, Inc. This announcement by Akeso, Inc. ( "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. About Akeso Akeso (HKEX: is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available, and 2 new drugs with 2 new indications are under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise. For more information, please visit and follow us on Linkedin. View original content: SOURCE Akeso, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store